medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2013, Number 1

<< Back Next >>

An Med Asoc Med Hosp ABC 2013; 58 (1)

Leucocytes serum levels in women with overactive bladder before and after of pharmacological treatment

Solano SSR, del Águila SAM, Rivas AL, Salomón KJ, Maldonado MEP

Language: Spanish
References: 13
Page: 21-25
PDF size: 74.33 Kb.


ABSTRACT

Objective: To determine if the plasma leucocytes levels differ in women with and without overactive bladder before and after of treatment. Method: Study with two lines. The first, cross-sectional design to compare plasma leucocytes levels in women with and without overactive bladder. The second, cohort design to compare plasma leucocytes levels in women with and without overactive bladder before and after of treatment. The diagnosis of overactive bladder was realized according to an autoapplicable questionnaire of eight questions «VH8». Results: The leucocytes plasma levels in women with and without overactive bladder before and after of treatment don´t have statistically significant difference between the groups. Conclusion: Women with overactive bladder don´t present greater plasma levels of leucocytes.


REFERENCES

  1. Bernard TH, Dirk R Robert M et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21:5-26

  2. Masaki Y, Koichi M, Takashi N, Makoto Y, Yukio H. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: Pathophysiology and pharmacotherapy of overactive bladder. J Pharmacol Sci 2010; 112: 128-134.

  3. Steers W. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 2002; 4 (suppl 4): S7-S18.

  4. Lowe EM, Anand P, Terenghi G et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997; 79: 572-577.

  5. Dupont MC, Spitsbergen JM, Kim KB et al. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 2001; 166: 1111-1118.

  6. Bjorling DE, Jacobsen HE, Blum JR et al. Intravesical Escherichia coli lipopolysaccharide stimulates an increase in bladder nerve growth factor. BJU Int 2001; 87: 697-702.

  7. Dupont M, Steers W, Tuttle JB. Inflammation induced neural plasticity in autonomic pathways supplying the bladder depends on NGF. Abstr Soc Neurosci 1994; 20:112.

  8. Vizzard MA, Erdman SL, de Groat WC. Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic bladder irritation. J Comp Neurol 1996; 370: 191.

  9. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006; 175 (5): 1773-1776.

  10. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 111: S460–S475, 2003.

  11. Baggiolini M: Chemokines in pathology and medicine. J Intern Med 2001; 250: 91-104.

  12. Bouchelouche K, Alvarez S, Horn T, Nordling J, Bouchelouche P. Human detrusor smooth muscle cells release Interleukin-6, interleukin-8, and rantes in response to proinflammatory cytokines Interleukin-1 and tumor necrosis factor. Urology 2006; 67: 214-219.

  13. Stephen BH, Steven MC, Warren SB. Diseño de investigaciones clínicas. 3a ed. Barcelona: Lippincott, Williams & Wilkins; 2008: 73-95.




2020     |     www.medigraphic.com